Having trouble accessing articles? Reset your cache.

BeiGene pushes back on short seller report

BeiGene refuted claims by short seller J Capital that the company has reported “fake sales” of its cancer portfolio from Celgene.

John Oyler, CEO of BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160), told BioCentury, “It’s easy to see the short-seller report for what it is,

Read the full 416 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers